Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
Skin condition flare-ups during the humid season are leading some individuals to avoid social events and celebrations.
Scabies is a skin condition caused by mites that get under your skin, causing you to itch. It’s extremely contagious and can ...
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...
Equip health professionals with resources to diagnose and treat conditions across all skin tones. Make mental health support ...
Medical Channel Asia's ongoing eczema survey reveals how chronic itch drives withdrawal, emotional strain, and missed celebrations during a period ...
HealthDay News — Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published in Nutrients.
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...